Topas Therapeutics GmbH

Falkenried 88, Haus A
20251 Hamburg GERMANY

+49 40 302089010

Press releases

  • Hamburg,
  • April 4, 2017

Paul Sekhri Joins Topas Therapeutics as Chairman of the Board

Topas Therapeutics GmbH (“Topas”), a privately held biotech company pursuing a novel liver-based immune tolerance approach, today announced the election of Paul Sekhri as Chairman of the Board effective immediately.

Paul Sekhri is currently CEO and President of the US based company Lycera Corporation (New York / NY & Ann Arbor / MI). Mr Sekhri has gained a wealth of experience in pharma, biotech and in the investment community – both in Europe and the US – by serving in various leading management positions in e.g. Sanofi, Teva, Novartis, Ariad and the TPG Capital group (TPG Biotech).

Pete Finan, former Chairman of Topas, stated: “We are delighted that Paul has joined our Board. With his wealth of experience he is an ideal fit to our team and adds significant value to support the next exciting steps in Topas’ development by building the bridge into the US with respect to the financial and partnering community.”

Paul Sekhri commented: “Topas clearly has breakthrough potential in the treatment of autoimmune diseases, allergies and anti-drug immune reactions. I am excited to become part of this professional team and to foster the development and commercialization of such innovative products.”

Following this appointment, the Board now consists of Paul Sekhri (Chairman), Pete Finan (Epidarex, Vice Chairman), Werner Lanthaler (Evotec), Karl Nägler (Gimv), Jan Adams (EMBL Ventures) and Erich Greiner (Cedrus Therapeutics).

About Topas Therapeutics
Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s natural immunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering. Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction, and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies. Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund. For additional information, please visit:

Topas Therapeutics GmbH
Dr. Timm-H. Jessen
CEO / Managing Director
Falkenried 88
20251 Hamburg

Media Relations Europe
MC Services AG
Anne Hennecke
Phone: +49 211 529252-22

Media Relations U.S.
Laurie Doyle
Phone: +1 339 8320752